KR101997939B1 - 담체-연결된 트레프로스티닐 전구약물 - Google Patents

담체-연결된 트레프로스티닐 전구약물 Download PDF

Info

Publication number
KR101997939B1
KR101997939B1 KR1020147006343A KR20147006343A KR101997939B1 KR 101997939 B1 KR101997939 B1 KR 101997939B1 KR 1020147006343 A KR1020147006343 A KR 1020147006343A KR 20147006343 A KR20147006343 A KR 20147006343A KR 101997939 B1 KR101997939 B1 KR 101997939B1
Authority
KR
South Korea
Prior art keywords
formula
alkyl
carrier
group
prodrug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020147006343A
Other languages
English (en)
Korean (ko)
Other versions
KR20140070545A (ko
Inventor
울리히 헤르셀
하랄트 라우
토르벤 레스만
니콜라 비섹
귈라움 마이트로
케네트 스프로게
토마스 베기
올리버 카일
요아킴 제틀러
Original Assignee
아센디스 파마 에이에스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아센디스 파마 에이에스 filed Critical 아센디스 파마 에이에스
Publication of KR20140070545A publication Critical patent/KR20140070545A/ko
Application granted granted Critical
Publication of KR101997939B1 publication Critical patent/KR101997939B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/72—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings and other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/641—Branched, dendritic or hypercomb peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020147006343A 2011-08-12 2012-08-10 담체-연결된 트레프로스티닐 전구약물 Expired - Fee Related KR101997939B1 (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP11177409.7 2011-08-12
EP11177409 2011-08-12
EP11195615 2011-12-23
EP11195615.7 2011-12-23
EP12165508.8 2012-04-25
EP12165508 2012-04-25
PCT/EP2012/065745 WO2013024052A1 (en) 2011-08-12 2012-08-10 Carrier-linked treprostinil prodrugs

Publications (2)

Publication Number Publication Date
KR20140070545A KR20140070545A (ko) 2014-06-10
KR101997939B1 true KR101997939B1 (ko) 2019-07-08

Family

ID=46690494

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147006343A Expired - Fee Related KR101997939B1 (ko) 2011-08-12 2012-08-10 담체-연결된 트레프로스티닐 전구약물

Country Status (14)

Country Link
US (2) US9561287B2 (OSRAM)
EP (1) EP2741781A1 (OSRAM)
JP (1) JP6092867B2 (OSRAM)
KR (1) KR101997939B1 (OSRAM)
CN (1) CN103857413A (OSRAM)
AU (1) AU2012296954B2 (OSRAM)
BR (1) BR112014003225A2 (OSRAM)
CA (1) CA2843883C (OSRAM)
HK (1) HK1198359A1 (OSRAM)
IL (1) IL230712A (OSRAM)
IN (1) IN2014CN00989A (OSRAM)
MX (1) MX349950B (OSRAM)
WO (1) WO2013024052A1 (OSRAM)
ZA (1) ZA201400977B (OSRAM)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6092867B2 (ja) * 2011-08-12 2017-03-08 アセンディス ファーマ エー／エス 担体連結しているトレプロスチニルプロドラッグ
EP2841109A1 (en) * 2012-04-25 2015-03-04 Ascendis Pharma A/S Prodrugs of hydroxyl-comprising drugs
JP6290243B2 (ja) 2012-12-07 2018-03-07 アセンディス ファーマ エー／エス 担体連結プロスタノイドプロドラッグ
EP3712142B1 (en) 2013-01-11 2022-07-06 Corsair Pharma, Inc. Prodrugs of treprostinil
US9505737B2 (en) 2013-01-11 2016-11-29 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
WO2014160638A1 (en) * 2013-03-25 2014-10-02 United Therapeutics Corporation Process of making prostacyclin compounds with linker thiol and pegylated forms
CN105407883A (zh) 2013-04-30 2016-03-16 联合治疗学有限公司 控释药物制剂
EP3808731A1 (en) 2013-10-25 2021-04-21 Insmed Incorporated Prostacyclin compounds
TWI685348B (zh) * 2014-05-08 2020-02-21 美國禮來大藥廠 速效胰島素組合物
US20170095432A1 (en) * 2014-06-13 2017-04-06 United Therapeutics Corporation Treprostinil formulations
WO2016010538A1 (en) * 2014-07-16 2016-01-21 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
CA2967385C (en) 2014-11-18 2023-05-16 Insmed Incorporated Methods of manufacturing treprostinil and treprostinil derivative prodrugs
TWI540121B (zh) 2014-12-01 2016-07-01 臺灣永光化學工業股份有限公司 曲前列環素二乙醇胺之合成方法及新穎中間體
WO2016088119A1 (en) 2014-12-03 2016-06-09 Steadymed Ltd Preservative-free treprostinil formulations and methods and devices for use with same
US9394227B1 (en) 2015-06-17 2016-07-19 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US9643911B2 (en) 2015-06-17 2017-05-09 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
EP3400022A1 (en) 2016-01-08 2018-11-14 Ascendis Pharma Growth Disorders A/S Controlled-release cnp agonists with low initial npr-b activity
WO2017118704A1 (en) 2016-01-08 2017-07-13 Ascendis Pharma Growth Disorders A/S Controlled-release cnp agonists with low npr-c binding
SMT202200466T1 (it) 2016-01-08 2023-01-13 Ascendis Pharma Growth Disorders As Profarmaci di cnp con legame a supporto in corrispondenza del raggruppamento ciclico
CA3008017C (en) 2016-01-08 2024-01-02 Ascendis Pharma Growth Disorders A/S Controlled-release cnp agonists with reduced side-effects
NZ743487A (en) 2016-01-08 2023-02-24 Ascendis Pharma Growth Disorders As Controlled-release cnp agonists with increased nep stability
WO2017118693A1 (en) 2016-01-08 2017-07-13 Ascendis Pharma Growth Disorders A/S Cnp prodrugs with large carrier moieties
SMT202400423T1 (it) 2016-03-01 2024-11-15 Ascendis Pharma Bone Diseases As Profarmaci di pth
CA3030376A1 (en) 2016-07-13 2018-01-18 Ascendis Pharma A/S Conjugation method for carrier-linked prodrugs
EP3512495B1 (en) 2016-09-15 2022-11-09 Camurus AB Prostacyclin analogue formulations
IL321464A (en) 2016-09-29 2025-08-01 Ascendis Pharma Growth Disorders As Combination therapy with controlled-release cnp agonists
PT3518982T (pt) 2016-09-29 2025-01-29 Ascendis Pharma Bone Diseases As Descoberta da dose incremental em compostos de pth de libertação controlada
NZ792622A (en) 2016-09-29 2025-08-29 Ascendis Pharma Bone Diseases As Pth compounds with low peak-to-trough ratios
RS64440B1 (sr) 2016-09-29 2023-09-29 Ascendis Pharma Bone Diseases As Režim doziranja za pth jedinjenje sa kontrolisanim oslobađanjem
EP3498283A1 (en) 2017-12-14 2019-06-19 Ipsol AG Glycosidic derivatives of treprostinil
DK3793587T3 (da) 2018-05-18 2025-07-21 Ascendis Pharma Bone Diseases As Startdosis af pth-konjugater
EP3856255A1 (en) 2018-09-26 2021-08-04 Ascendis Pharma A/S Treatment of infections
WO2020064847A1 (en) 2018-09-26 2020-04-02 Ascendis Pharma A/S Degradable hyaluronic acid hydrogels
EP3856256A1 (en) 2018-09-26 2021-08-04 Ascendis Pharma A/S Novel hydrogel conjugates
US20220054476A1 (en) 2019-01-04 2022-02-24 Ascendis Pharma Oncology Division A/S Sustained local drug levels for innate immune agonists
BR112021011592A2 (pt) 2019-01-04 2021-10-26 Ascendis Pharma Oncology Division A/S Conjugados de agonistas de receptor de reconhecimento de padrão
CA3125541A1 (en) 2019-01-04 2020-07-09 Ascendis Pharma Oncology Division A/S Minimization of systemic inflammation
WO2020141223A1 (en) 2019-01-04 2020-07-09 Ascendis Pharma A/S Induction of sustained local inflammation
EP3923905A1 (en) 2019-02-11 2021-12-22 Ascendis Pharma Bone Diseases A/S Liquid pharmaceutical formulations of pth conjugates
US12377133B2 (en) 2019-02-11 2025-08-05 Ascendis Pharma Growth Disorders A/S Dry pharmaceutical formulations of CNP conjugates
US11458098B2 (en) 2019-04-29 2022-10-04 Insmed Incorporated Dry powder compositions of treprostinil prodrugs and methods of use thereof
WO2020254617A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Anti-ctla4 compounds with localized pk properties
WO2020254607A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Anti-ctla4 compounds with localized pd properties
WO2020254613A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Controlled-release tyrosine kinase inhibitor compounds with localized pk properties
AU2020295725A1 (en) 2019-06-21 2021-12-02 Ascendis Pharma Oncology Division A/S Anti-CTLA4 conjugates
WO2020254612A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Controlled-release tyrosine kinase inhibitor compounds with localized pd properties
EP3986478A1 (en) 2019-06-21 2022-04-27 Ascendis Pharma Oncology Division A/S Tyrosine kinase inhibitor conjugates
JP2020011957A (ja) * 2019-07-22 2020-01-23 コルセア ファーマ インコーポレイテッド トレプロスチニル誘導体化合物およびその使用方法
IL294357A (en) 2020-01-13 2022-08-01 Ascendis Pharma Bone Diseases As Hypoparathyroidism treatment
WO2021224169A1 (en) 2020-05-04 2021-11-11 Ascendis Pharma A/S Hydrogel irradiation
WO2021252446A1 (en) 2020-06-09 2021-12-16 United Therapeutics Corporation Fumaryl diketopiperidine prodrugs of treprostinil
IL301411A (en) 2020-09-28 2023-05-01 Ascendis Pharma Bone Diseases As Improvement of physical and mental well-being of patients with hypoparathyroidism
JP7138685B2 (ja) * 2020-10-26 2022-09-16 コルセア ファーマ インコーポレイテッド トレプロスチニル誘導体化合物およびその使用方法
WO2022194195A1 (zh) * 2021-03-16 2022-09-22 江苏恒瑞医药股份有限公司 一种曲前列环素衍生物及其用途
WO2023046732A1 (en) 2021-09-22 2023-03-30 Ascendis Pharma Bone Diseases A/S Long-acting pth compound treatments
WO2023110758A1 (en) 2021-12-13 2023-06-22 Ascendis Pharma Growth Disorders A/S Effective doses of cnp conjugates
AU2022409306A1 (en) 2021-12-13 2024-06-06 Ascendis Pharma Oncology Division A/S Cancer treatments with tlr7/8 agonists
CN116444377A (zh) * 2022-01-07 2023-07-18 广州楷石医药有限公司 一种氧化氮供体型曲前列尼尔类衍生物及其药物组合物和用途
JP2025522281A (ja) 2022-05-23 2025-07-15 アセンディス ファーマ グロース ディスオーダーズ エー／エス Ｃｎｐ化合物の液体医薬製剤
AU2023374533A1 (en) 2022-11-02 2025-04-10 Ascendis Pharma Bone Diseases A/S Pth treatment regimen comprising two pth compounds
WO2024104922A1 (en) 2022-11-14 2024-05-23 Ascendis Pharma Growth Disorders A/S Method of improving skeletal muscle function
AU2024240722A1 (en) 2023-03-20 2025-09-18 Ascendis Pharma Growth Disorders A/S Method of treatment of a thoracolumbar deformity in a human subject with achondroplasia
WO2025051711A1 (en) 2023-09-04 2025-03-13 Ascendis Pharma Bone Diseases A/S Pth treatment of chronic kidney disease

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010518122A (ja) * 2007-02-09 2010-05-27 ユナイテッド セラピューティクス コーポレーション 間質性肺疾患および喘息のためのトレプロスチニル処置
WO2011012715A1 (en) * 2009-07-31 2011-02-03 Ascendis Pharma As Biodegradable polyethylene glycol based water-insoluble hydrogels

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4306075A (en) 1980-03-28 1981-12-15 The Upjohn Company Composition and process
CA1241324A (en) 1984-03-08 1988-08-30 Paul A. Aristoff Interphenylene carbacyclin derivatives
CN1354622A (zh) * 1999-03-31 2002-06-19 联合治疗公司 前列腺素类化合物、组合物和治疗外周血管疾病和肺动脉高压的方法
PL1620118T3 (pl) * 2003-04-08 2014-11-28 Yeda Res & Dev Leki odwracalnie pegylowane
DE602004022982D1 (de) * 2003-12-16 2009-10-15 United Therapeutics Corp Verwendung von treprostinil zur verbesserung der nierenfunktion
US7968085B2 (en) 2004-07-05 2011-06-28 Ascendis Pharma A/S Hydrogel formulations
EP1625856A1 (en) 2004-08-13 2006-02-15 Complex Biosystems GmbH Hydrogel polymeric conjugates of a prodrug
ATE502114T1 (de) * 2007-06-21 2011-04-15 Univ Muenchen Tech Biologisch aktive proteine mit erhöhter in-vivo- und/oder in-vitro-stabilität
PL3050576T3 (pl) 2008-04-29 2021-10-25 Ascendis Pharma Endocrinology Division A/S Pegylowane związki rekombinowanego ludzkiego hormonu wzrostu
WO2010014258A2 (en) * 2008-08-01 2010-02-04 Nektar Therapeutics Al, Corporation Conjugates having a releasable linkage
KR101671537B1 (ko) * 2008-08-11 2016-11-01 넥타르 테라퓨틱스 다분지형 중합체 알카노에이트 컨쥬게이트
EP2898900B1 (en) * 2008-09-19 2017-11-15 Nektar Therapeutics Polymer conjugates of ziconotide
WO2010068754A2 (en) 2008-12-10 2010-06-17 Paka Pulmonary Pharmaceuticals, Inc. Methods and compositions for delivery of medicaments to the lungs
EP2440228B8 (en) * 2009-06-08 2023-02-22 Amunix Operating Inc. Glucose-regulating polypeptides and methods of making and using same
WO2011042450A1 (en) * 2009-10-06 2011-04-14 Ascendis Pharma As Carrier linked paliperidone prodrugs
JP6092867B2 (ja) * 2011-08-12 2017-03-08 アセンディス ファーマ エー／エス 担体連結しているトレプロスチニルプロドラッグ

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010518122A (ja) * 2007-02-09 2010-05-27 ユナイテッド セラピューティクス コーポレーション 間質性肺疾患および喘息のためのトレプロスチニル処置
WO2011012715A1 (en) * 2009-07-31 2011-02-03 Ascendis Pharma As Biodegradable polyethylene glycol based water-insoluble hydrogels

Also Published As

Publication number Publication date
IN2014CN00989A (OSRAM) 2015-04-10
IL230712A0 (en) 2014-03-31
US10729778B2 (en) 2020-08-04
US20140296150A1 (en) 2014-10-02
WO2013024052A1 (en) 2013-02-21
BR112014003225A2 (pt) 2017-03-01
MX2014001497A (es) 2014-04-25
US20190105400A1 (en) 2019-04-11
IL230712A (en) 2017-08-31
EP2741781A1 (en) 2014-06-18
AU2012296954B2 (en) 2016-09-15
ZA201400977B (en) 2017-11-29
US9561287B2 (en) 2017-02-07
KR20140070545A (ko) 2014-06-10
HK1198359A1 (en) 2015-04-10
MX349950B (es) 2017-08-22
AU2012296954A1 (en) 2014-02-20
JP2014527050A (ja) 2014-10-09
JP6092867B2 (ja) 2017-03-08
CN103857413A (zh) 2014-06-11
CA2843883A1 (en) 2013-02-21
CA2843883C (en) 2020-04-28

Similar Documents

Publication Publication Date Title
KR101997939B1 (ko) 담체-연결된 트레프로스티닐 전구약물
KR20140082649A (ko) 프로스타사이클린의 서방형 조성물
US20250127859A1 (en) Cnp prodrugs with large carrier moieties
US12239689B2 (en) Controlled-release CNP agonists with low initial NPR-B activity
US20210069339A1 (en) Cnp prodrugs
CA2891949C (en) Carrier-linked prostanoid prodrugs
EP3400019B1 (en) Cnp prodrugs with carrier attachment at the ring moiety
CA3007987C (en) Controlled-release cnp agonists with low npr-c binding
HK1197733A (en) Sustained release composition of prostacyclin
HK1197731A (en) Carrier-linked treprostinil prodrugs
HK1262548A1 (en) Cnp prodrugs with carrier attachment at the ring moiety
HK1262548B (en) Cnp prodrugs with carrier attachment at the ring moiety

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20220703

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20220703

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000